Abstract
Nucleotide metabolism has been targeted for many years and in various clinical settings, including cancer. The increased knowledge of certain enzymes involved in this metabolism and associated cellular processes accumulated over the last few years, gives important information related to the druggability of certain proteins and the use of inhibitors for others. Here, we review recent data on such enzymes with a major interest in drug development, i.e. SAMHD1 and the proteins of the NUDIX family. These include information on their roles in cancer progression, correlations with clinical outcomes in cancer patients, and the development and study of enzymatic inhibitors.
Keywords: NUDIX, MTH1, SAMHD1, cancer, treatment, inhibitors.
Current Medicinal Chemistry
Title:Targeting the Nucleotide Metabolism Proteins of the NUDIX Family and SAMHD1 in Cancer
Volume: 28 Issue: 21
Author(s): Prescillia Forey, Emeline Cros-Perrial, Charles Dumontet and Lars Petter Jordheim*
Affiliation:
- Univ Lyon, Universite Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Leon Berard, Centre de Recherche en Cancerologie de Lyon, Lyon, 69008,France
Keywords: NUDIX, MTH1, SAMHD1, cancer, treatment, inhibitors.
Abstract: Nucleotide metabolism has been targeted for many years and in various clinical settings, including cancer. The increased knowledge of certain enzymes involved in this metabolism and associated cellular processes accumulated over the last few years, gives important information related to the druggability of certain proteins and the use of inhibitors for others. Here, we review recent data on such enzymes with a major interest in drug development, i.e. SAMHD1 and the proteins of the NUDIX family. These include information on their roles in cancer progression, correlations with clinical outcomes in cancer patients, and the development and study of enzymatic inhibitors.
Export Options
About this article
Cite this article as:
Forey Prescillia , Cros-Perrial Emeline , Dumontet Charles and Jordheim Petter Lars *, Targeting the Nucleotide Metabolism Proteins of the NUDIX Family and SAMHD1 in Cancer, Current Medicinal Chemistry 2021; 28 (21) . https://dx.doi.org/10.2174/0929867328666201125120422
DOI https://dx.doi.org/10.2174/0929867328666201125120422 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lactobacillus GG (LGG) Peptides Can Inhibit Antibiotic-Resistant Bacteria Growth
Anti-Infective Agents in Medicinal Chemistry Phytochemicals as Adjunctive with Conventional Anticancer Therapies
Current Pharmaceutical Design Concepts for Nano-delivery of Therapeutic Immunomodulatory Agents
Current Bionanotechnology (Discontinued) Current Strategy for Cisplatin Delivery
Current Cancer Drug Targets Role of Unani Medicines in Cancer Control and Management
Current Drug Therapy Hypericin Lights Up the Way for the Potential Treatment of Nasopharyngeal Cancer by Photodynamic Therapy
Current Clinical Pharmacology Therapeutic Potential and Pharmaceutical Applications of <i>Cucurbita</i>
Current Nutrition & Food Science Chemical and Radiochemical Considerations in Radiolabeling with α-Emitting Radionuclides
Current Radiopharmaceuticals Radiosensitization of Prostate Cancer by Soy Isoflavones
Current Cancer Drug Targets Polyphenols: Biological Activities, Molecular Targets, and the Effect of Methylation
Current Molecular Pharmacology Meet Our Editorial Board Member
Current Neuropharmacology Meet Our Editorial Board Member
Current Protein & Peptide Science SJSZ Glycoprotein (38 kDa) Inhibits Cell Cycle and Oxidative Stress in N-Methyl-N`- nitro-N-nitrosoguanidine-induced ICR Mice
Anti-Cancer Agents in Medicinal Chemistry Pharmacometrics in Dose Finding or Dose Optimization of Anti-Retroviral and Anti-Tubercular Drugs
Infectious Disorders - Drug Targets Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials
Current Diabetes Reviews Recent Patents on Genes and Gene Sequences Useful for Developing Breast Cancer Detection Systems
Recent Patents on DNA & Gene Sequences Antineoplastic Potential of Medicinal Plants
Recent Patents on Biotechnology Ghrelin as a Potential Anti-Obesity Target
Current Pharmaceutical Design New Insight Into A1 Adenosine Receptors in Diabetes Treatment
Current Pharmaceutical Design Secreted Heat Shock Protein-90α: A More Effective and Safer Target for Anti-Cancer Drugs?
Current Signal Transduction Therapy